Nocion Therapeutics Presents Data on Preclinical and Clinical Development of Taplucainium, a Novel, Charged Sodium Channel Blocker, as a potential treatment for Chronic Cough at the 13th London International Cough Symposium
15 Julio 2024 - 7:00AM
Business Wire
- Positive results including complete inhibition of cough
response in preclinical models and a favorable safety profile in
three clinical studies support the initiation of a Phase 2b
clinical trial of taplucainium in 240 subjects in the second half
of 2024.
Nocion Therapeutics, Inc., a clinical stage biopharmaceutical
company developing novel small molecule charged sodium channel
blockers called “nocions”, that selectively affect actively firing
nociceptors for the treatment of serious conditions involving
cough, itch, and pain, today announced the presentation of progress
in the development of taplucainium, a novel, charged sodium channel
blocker, as a potential treatment for chronic cough at the 13th
London International Cough Symposium. The presentation and poster
will be given by Bernard Silverman, MD., Nocion’s Chief Medical
Officer.
“We are excited with the strong progress that we have made
developing taplucainium as a treatment for chronic cough with the
ability to address this significant unmet medical need,” said Dr.
Silverman. “We look forward to the start of our ASPIRE (Phase 2b)
clinical trial of taplucainium in 240 chronic cough patients in the
second half of 2024.”
ABOUT TAPLUCAINIUM Taplucainium (formerly NTX-1175) is a
proprietary molecule in the novel class of charged sodium channel
blockers that allows for specific silencing of activated/inflamed
nociceptors while having minimal local off-target effects or
systemic exposure. Unlike other investigative cough therapies, such
as P2X3-antagonists, TRPA1-antagonists and TRPM8-agonists, which
target a specific large pore channel, taplucainium works downstream
by selectively targeting the sodium channels in activated
nociceptors which are the target of these large pore channels.
Taplucainium is formulated into a dry powder for inhalation and,
once inhaled, gains access to the pulmonary nociceptors through any
open large pore channel including P2X, TRPV, TRPA and TRPM channels
whereupon it inhibits the sodium channels responsible for
initiating the pathological cough response. The broader mechanism
of taplucainium has shown significant antitussive effects in
preclinical models of cough. Combined with good preliminary safety
and efficacy data from earlier stage clinical work, this forms the
basis for its investigation not just in chronic cough but in other
cough indications as well.
ABOUT NOCION Nocion Therapeutics is a biopharmaceutical
company developing novel small molecule charged sodium channel
blockers called “nocions” that selectively affect actively firing
nociceptors for the treatment of serious conditions involving
cough, itch, and pain. The company’s mission is to safely alleviate
suffering for millions of patients with conditions arising from
activated sensory neurons. Working with Harvard’s Office of
Technology Development, Nocion was founded on an exclusive license
to foundational intellectual property from Harvard University and
Boston Children’s Hospital. Venture investors in Nocion include
Arkin Bio Capital, Canaan Partners, F-Prime Capital, Lumira
Ventures, Mass General Brigham Ventures, Mission BioCapital,
Monograph Capital, Morningside and Osage University Partners. For
more information, visit: www.nociontx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240715222816/en/
Stephanie Gillis pr@nociontx.com